开云app官网登录入口网页版-官方正版

#AKI#

70篇内容 | 2203人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2220224, encodeId=3d832220224d3, content=<a href='/topic/show?id=7cd15239687' target=_blank style='color:#2F92EE;'>#急性肾损伤#</a> <a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=Adv Sci：陆军军医大学曾春雨等团队合作开发新的纳米载体，用于缓解急性肾损伤, objectType=article, longId=838834, objectId=8d8f838834b4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240805/1722842512326_8538692.jpg, objectUrl=/article/show_article.do?id=8d8f838834b4, replyNumber=0, likeNumber=58, createdTime=2024-08-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8d8f838834b4, moduleTitle=Adv Sci：陆军军医大学曾春雨等团队合作开发新的纳米载体，用于缓解急性肾损伤, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8d8f838834b4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1341150, encodeId=ddbc1341150c8, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=Crit Care：伴有AKI的危重患者血清IL-17水平较高且与患者较差预后相关, objectType=article, longId=724388, objectId=4e89e24388b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e89e24388b1, replyNumber=0, likeNumber=92, createdTime=2022-04-17, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e89e24388b1, moduleTitle=Crit Care：伴有AKI的危重患者血清IL-17水平较高且与患者较差预后相关, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4e89e24388b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341149, encodeId=e25e13411496d, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=CHMP对 Kineret (anakinra) 治疗COVID-19持积极意见, objectType=article, longId=292250, objectId=43db292250ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43db292250ee, replyNumber=0, likeNumber=71, createdTime=2021-12-21, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43db292250ee, moduleTitle=CHMP对 Kineret (anakinra) 治疗COVID-19持积极意见, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=43db292250ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341148, encodeId=f142134114807, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=JEADV:替曲吉珠单抗（ tildrakizumab ）对中度至重度银屑病患者第28周停药后复发时间的研究, objectType=article, longId=216745, objectId=b9a4216e45c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9a4216e45c3, replyNumber=0, likeNumber=116, createdTime=2021-09-08, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9a4216e45c3, moduleTitle=JEADV:替曲吉珠单抗（ tildrakizumab ）对中度至重度银屑病患者第28周停药后复发时间的研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b9a4216e45c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341147, encodeId=3c87134114ee5, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=多灶性白质脑病如何治疗？NT-I7（efineptakin alfa）将进入临床试验阶段, objectType=article, longId=207572, objectId=421220e57265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=421220e57265, replyNumber=0, likeNumber=77, createdTime=2021-02-26, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=421220e57265, moduleTitle=多灶性白质脑病如何治疗？NT-I7（efineptakin alfa）将进入临床试验阶段, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=421220e57265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341146, encodeId=b0af134114611, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, objectType=article, longId=207010, objectId=0c9920e0107e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c9920e0107e, replyNumber=0, likeNumber=121, createdTime=2021-02-11, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c9920e0107e, moduleTitle=JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0c9920e0107e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341145, encodeId=19da134114529, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=Crit Care：脓毒症相关AKI患者肾脏线粒体DNA损伤和线粒体质量减少有关, objectType=article, longId=206257, objectId=f30a20625e77, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f30a20625e77, replyNumber=0, likeNumber=84, createdTime=2021-01-27, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f30a20625e77, moduleTitle=Crit Care：脓毒症相关AKI患者肾脏线粒体DNA损伤和线粒体质量减少有关, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f30a20625e77)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341144, encodeId=50091341144c1, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=JASN：严重急性呼吸系统综合症或新冠肺炎患者的AKI和主要不良临床结局的风险, objectType=article, longId=206148, objectId=ce24206148bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce24206148bf, replyNumber=0, likeNumber=65, createdTime=2021-01-25, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce24206148bf, moduleTitle=JASN：严重急性呼吸系统综合症或新冠肺炎患者的AKI和主要不良临床结局的风险, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ce24206148bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341143, encodeId=1980134114348, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=J Am Soc Nephrol：抗IL-6抗体clazakizumab对抗体介导的排斥反应的有利作用, objectType=article, longId=205782, objectId=e8ea205e8249, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8ea205e8249, replyNumber=0, likeNumber=0, createdTime=2021-01-17, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8ea205e8249, moduleTitle=J Am Soc Nephrol：抗IL-6抗体clazakizumab对抗体介导的排斥反应的有利作用, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e8ea205e8249)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341142, encodeId=ca221341142e2, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=琅铧医药获发作性睡病治疗药物Wakix(pitolisant) 中国**权益, objectType=article, longId=203242, objectId=a3a220324236, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3a220324236, replyNumber=0, likeNumber=81, createdTime=2020-11-12, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3a220324236, moduleTitle=琅铧医药获发作性睡病治疗药物Wakix(pitolisant) 中国**权益, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a3a220324236)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341141, encodeId=1f3213411413d, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=诺华IL-1β单抗canakinumab治疗新冠COVID-19：未能提高生存率, objectType=article, longId=203185, objectId=8a9e203185f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a9e203185f0, replyNumber=0, likeNumber=88, createdTime=2020-11-11, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a9e203185f0, moduleTitle=诺华IL-1β单抗canakinumab治疗新冠COVID-19：未能提高生存率, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8a9e203185f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341140, encodeId=e7931341140ac, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=JASN：2型糖尿病患者AKI与CKD之间的关系, objectType=article, longId=202017, objectId=12ab20201eaa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12ab20201eaa, replyNumber=0, likeNumber=103, createdTime=2020-10-14, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12ab20201eaa, moduleTitle=JASN：2型糖尿病患者AKI与CKD之间的关系, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=12ab20201eaa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341139, encodeId=05371341139c2, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=Am J Kidney Dis：肾脏损伤和修复的生物标志物是造影剂相关AKI的预测因子, objectType=article, longId=198675, objectId=91e71986e547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91e71986e547, replyNumber=0, likeNumber=101, createdTime=2020-08-05, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91e71986e547, moduleTitle=Am J Kidney Dis：肾脏损伤和修复的生物标志物是造影剂相关AKI的预测因子, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=91e71986e547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341138, encodeId=a5ac13411389c, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=Arthritis Rheumatol：Canakinumab在5岁及以下CAPS患者中的治疗作用, objectType=article, longId=198102, objectId=91da198102bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91da198102bf, replyNumber=0, likeNumber=127, createdTime=2020-07-28, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91da198102bf, moduleTitle=Arthritis Rheumatol：Canakinumab在5岁及以下CAPS患者中的治疗作用, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=91da198102bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341137, encodeId=0048134113ee4, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=FDA批准Still病的**药物：诺华的白细胞介素-1单抗canakinumab, objectType=article, longId=196063, objectId=e34d196063ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e34d196063ce, replyNumber=0, likeNumber=76, createdTime=2020-06-19, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e34d196063ce, moduleTitle=FDA批准Still病的**药物：诺华的白细胞介素-1单抗canakinumab, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e34d196063ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341136, encodeId=7e431341136a4, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=抗体药物偶联物ILUMYA（tildrakizumab-asmn）治疗中重度斑块状牛皮癣：长期安全性有效性良好, objectType=article, longId=195863, objectId=9d4319586365, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d4319586365, replyNumber=0, likeNumber=82, createdTime=2020-06-15, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d4319586365, moduleTitle=抗体药物偶联物ILUMYA（tildrakizumab-asmn）治疗中重度斑块状牛皮癣：长期安全性有效性良好, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9d4319586365)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341135, encodeId=cfe2134113519, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=Lancet Rheumato：Anakinra治疗重症新冠肺炎患者, objectType=article, longId=195185, objectId=262d19518599, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262d19518599, replyNumber=0, likeNumber=86, createdTime=2020-06-04, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262d19518599, moduleTitle=Lancet Rheumato：Anakinra治疗重症新冠肺炎患者, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=262d19518599)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341134, encodeId=808c134113424, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=IL-6试验令人失望后，诺华将测试IL-1单抗canakinumab用于抵抗新冠COVID-19的细胞因子风暴, objectType=article, longId=193314, objectId=6b1119331457, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b1119331457, replyNumber=0, likeNumber=128, createdTime=2020-05-03, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b1119331457, moduleTitle=IL-6试验令人失望后，诺华将测试IL-1单抗canakinumab用于抵抗新冠COVID-19的细胞因子风暴, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6b1119331457)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341133, encodeId=2aa613411336b, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=ASCO 2020年度胃肠道癌专题讨论会：礼来的pegilodecakin未达到试验预期, objectType=article, longId=186805, objectId=c58218680512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c58218680512, replyNumber=0, likeNumber=79, createdTime=2020-01-29, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c58218680512, moduleTitle=ASCO 2020年度胃肠道癌专题讨论会：礼来的pegilodecakin未达到试验预期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c58218680512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1341132, encodeId=7d741341132b0, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, objectTitle=JASN：免疫检查点抑制剂相关AKI的临床特征和结局, objectType=article, longId=186100, objectId=1ef318610083, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ef318610083, replyNumber=0, likeNumber=95, createdTime=2020-01-13, rootId=0, userName=ms4468361851264128, userId=f7482500171, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ef318610083, moduleTitle=JASN：免疫检查点抑制剂相关AKI的临床特征和结局, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1ef318610083)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

AKI

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#急性肾损伤# #AKI#

Adv Sci：陆军军医大学曾春雨等团队合作开发新的纳米载体，用于缓解急性肾损伤

2024-08-15发表于上海

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

Crit Care：伴有AKI的危重患者血清IL-17水平较高且与患者较差预后相关

2022-04-17

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

CHMP对 Kineret (anakinra) 治疗COVID-19持积极意见

2021-12-21

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

JEADV:替曲吉珠单抗（ tildrakizumab ）对中度至重度银屑病患者第28周停药后复发时间的研究

2021-09-08

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

多灶性白质脑病如何治疗？NT-I7（efineptakin alfa）将进入临床试验阶段

2021-02-26

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效

2021-02-11

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

Crit Care：脓毒症相关AKI患者肾脏线粒体DNA损伤和线粒体质量减少有关

2021-01-27

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

JASN：严重急性呼吸系统综合症或新冠肺炎患者的AKI和主要不良临床结局的风险

2021-01-25

zhouqu_8 (审核中...)

前往app查看评论内容

#AKI#

J Am Soc Nephrol：抗IL-6抗体clazakizumab对抗体介导的排斥反应的有利作用

2021-01-17

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

琅铧医药获发作性睡病治疗药物Wakix(pitolisant) 中国**权益

2020-11-12

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

诺华IL-1β单抗canakinumab治疗新冠COVID-19：未能提高生存率

2020-11-11

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

JASN：2型糖尿病患者AKI与CKD之间的关系

2020-10-14

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

Am J Kidney Dis：肾脏损伤和修复的生物标志物是造影剂相关AKI的预测因子

2020-08-05

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

Arthritis Rheumatol：Canakinumab在5岁及以下CAPS患者中的治疗作用

2020-07-28

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

FDA批准Still病的**药物：诺华的白细胞介素-1单抗canakinumab

2020-06-19

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

抗体药物偶联物ILUMYA（tildrakizumab-asmn）治疗中重度斑块状牛皮癣：长期安全性有效性良好

2020-06-15

zhaojie88 (审核中...)

前往app查看评论内容

#AKI#

Lancet Rheumato：Anakinra治疗重症新冠肺炎患者

2020-06-04

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

IL-6试验令人失望后，诺华将测试IL-1单抗canakinumab用于抵抗新冠COVID-19的细胞因子风暴

2020-05-03

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

ASCO 2020年度胃肠道癌专题讨论会：礼来的pegilodecakin未达到试验预期

2020-01-29

ms4468361851264128 (审核中...)

前往app查看评论内容

#AKI#

JASN：免疫检查点抑制剂相关AKI的临床特征和结局

2020-01-13

科室
- - 订阅+
  - 更多科室
工具
服务